1
|
Nwannunu CE, Shah R, Limmer AL. Management of Primary Small-Vessel Vasculitis. Skin Therapy Lett 2020; 25:5-8. [PMID: 32510891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Small-vessel vasculitides (SVV) are a group of disorders that occur due to primarily systemic inflammation or as sequelae of an infection, malignancy, or other rheumatic disease. Arising in any organ including the skin, the clinical features of SVV encompass a variety of manifestations. A comprehensive diagnostic assessment should be performed as management protocols widely differ. Although rare, physicians should be familiar with the common types of SVV to ensure prompt management and prevention of severe, life-threatening end-organ damage. Given the variable manifestations and associated etiologies of SVV, the following review aims to discuss the pathogenesis of more prevalent SVVs, highlight distinguishing features to aid in patient evaluation and diagnosis, and examine evidence-based management options for treatment and care.
Collapse
Affiliation(s)
- Crystal E Nwannunu
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
| | - Radhika Shah
- Texas A&M University College of Medicine, Dallas, TX, USA
| | | |
Collapse
|
2
|
Limmer AL, Nwannunu CE, Patel RR, Mui UN, Tyring SK. Management of Ichthyosis: A Brief Review. Skin Therapy Lett 2020; 25:5-7. [PMID: 32023022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The ichthyoses, also termed the disorders of keratinization, are a heterogenous group of skin diseases in which a distinctive horny layer arises secondary to excessive transepidermal water loss. Although occasionally acquired, the majority of ichthyoses are inherited and can be pinpointed to characteristic genetic mutations. Management depends on disease severity and includes topical agents and lifestyle modifications with or without oral retinoids. Genetic counseling is also an important consideration. This review aims to highlight advances in our understanding of disease pathogenesis as well as the holistic approach necessary to adequately manage ichthyosis patients.
Collapse
Affiliation(s)
- Allison L Limmer
- Department of Dermatology, McGovern Medical School at The University of Texas Health Sciences Center at Houston, Houston, TX, USA
| | - Crystal E Nwannunu
- Department of Dermatology, McGovern Medical School at The University of Texas Health Sciences Center at Houston, Houston, TX, USA
| | | | - Uyen N Mui
- Center for Clinical Studies, Houston, TX, USA
| | - Stephen K Tyring
- Department of Dermatology, McGovern Medical School at The University of Texas Health Sciences Center at Houston, Houston, TX, USA
- Center for Clinical Studies, Houston, TX, USA
| |
Collapse
|
3
|
Shah RA, Nwannunu CE, Limmer AL, Patel RR, Mui UN, Tyring SK. Brief Update on Dermatologic Uses of Methotrexate. Skin Therapy Lett 2019; 24:5-8. [PMID: 31801013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Methotrexate (MTX), an agent originally intended for anti-neoplastic use, has been successfully employed in the treatment of a variety of dermatologic conditions. In addition to its multiple clinical indications, variable dosing and modes of administration make it a viable option for patients of all ages and most comorbidities. MTX is a folate analog that antagonizes dihydrofolate reductase, thus inhibiting thymidylate synthesis and, ultimately, the production of pyrimidine. Depending on dosage, MTX can function as an anti-inflammatory agent, immunomodulator, or antimetabolite. Patients suffering from psoriasis have benefited from MTX in addition to those with atopic dermatitis, chronic urticaria, pemphigus vulgaris, bullous pemphigoid, cutaneous lupus erythematosus, cutaneous sarcoidosis, and mycosis fungoides. Although patients with these conditions can benefit from MTX treatment, the drug can cause adverse sequelae, including hematologic, pulmonary, gastrointestinal, and hepatic side effects. Therefore, the drug should be administered under careful physician supervision.
Collapse
Affiliation(s)
| | - Crystal E. Nwannunu
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
| | - Allison L. Limmer
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
| | | | | | - Stephen K. Tyring
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
- Center for Clinical Studies, Houston, TX, USA
| |
Collapse
|
4
|
Shah RA, Limmer AL, Nwannunu CE, Patel RR, Mui UN, Tyring SK. Shingrix for Herpes Zoster: A Review. Skin Therapy Lett 2019; 24:5-7. [PMID: 31339679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Herpes zoster (HZ), also known as shingles, results from reactivation of the latent varicella-zoster virus (VZV), which commonly causes chickenpox in childhood. Greater than 90% of adults are infected with this virus, putting them at risk for reactivation. HZ presents as a painful, vesicular rash distributed in a unilateral and dermatomal pattern along dorsal root or cranial nerve ganglia. The rash often presents with prodromal symptoms and progresses to include clear vesicular clusters, evolving through stages of pustulation, ulceration, and crusting. HZ therapy currently involves the use of antiviral agents and pain management; however, HZ prophylaxis has been strongly recommended in older adults through vaccination with a live attenuated vaccine, Zostavax®. A new recombinant subunit vaccine, HZ/su (Shingrix®), is the subject of this review. In clinical trials, HZ/su demonstrated an overall vaccine efficacy of 97.2% among participants 50 years of age or older, indicating a significantly reduced risk of HZ in these individuals. Shingrix® was approved by the US FDA in October 2017 as HZ prophylaxis.
Collapse
Affiliation(s)
- Radhika A Shah
- Texas A&M University College of Medicine, Dallas, TX, USA
| | - Allison L Limmer
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
| | - Crystal E Nwannunu
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
| | | | | | - Stephen K Tyring
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
- Center for Clinical Studies, Houston, TX, USA
| |
Collapse
|
5
|
Limmer AL, Nwannunu CE, Shah R, Coleman K, Patel RR, Mui UN, Tyring SK. Topical Diacerein Ointment for Epidermolysis Bullosa Simplex: A Review. Skin Therapy Lett 2019; 24:7-9. [PMID: 31095348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Epidermolysis bullosa (EB) is a group of rare mucocutaneous fragility disorders often presenting in infancy and early childhood with painful blistering of the skin and mucous membranes. The severity of EB blister burden varies by disease subtype. Studies have shown that patients with generalized severe epidermolysis bullosa simplex (EBS), a variant characterized by extreme fragility, develop blisters in the setting of overproduced, mutated K14 protein, a component of the intermediate filament integral in keratinocyte stability, and constitutive activation of interleukin (IL)-1 , a pro-inflammatory cytokine that promotes the hyperproliferation of keratinocytes. Diacerein, a rhein prodrug and anthraquinone, has been shown to reduce expression of K14 and inhibit IL-1 converting enzyme. In clinical trials, topical 1% diacerein was shown to be an effective and safe, non-invasive treatment for patients suffering from EBS. This review examines the clinical trials of topical diacerein and its role in EBS. Diacerein ointment was granted US FDA Rare Pediatric Disease designation in May 2018 and Fast Track development designation in August 2018.
Collapse
Affiliation(s)
- Allison L Limmer
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
| | | | - Radhika Shah
- Texas A&M University College of Medicine, Dallas, TX, USA
| | - Kendall Coleman
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
| | | | | | - Stephen K Tyring
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
- Center for Clinical Studies, Houston, TX, USA
| |
Collapse
|
6
|
Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, Tyring SK. Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis. Skin Therapy Lett 2019; 24:1-3. [PMID: 30970203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Hyperhidrosis is a condition characterized by excessive sweat production beyond which is physiologically necessary for thermal regulation. Affecting over 4.8% of the United States population, studies have shown that severe primary hyperhidrosis interferes with daily activities and can be considered intolerable, negatively impacting a patient’s quality of life. Glycopyrronium tosylate is a topical anticholinergic agent that reduces sweat production by blocking the activation of acetylcholine receptors in peripheral sweat glands. In clinical trials, topical glycopyrronium tosylate, a pre-moistened cloth containing 2.4% glycopyrronium solution, was shown to be an effective, safe and non-invasive treatment for patients suffering from primary hyperhidrosis. This review examines the clinical trials of topical glycopyrronium tosylate and its role in primary hyperhidrosis. Glycopyrronium tosylate was recently US FDA-approved (as of June 2018) to manage patients with primary axillary hyperhidrosis.
Collapse
Affiliation(s)
- Crystal E Nwannunu
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
| | - Allison L Limmer
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
| | - Kendall Coleman
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
| | - Radhika Shah
- Texas A&M University College of Medicine, Dallas, TX, USA
| | | | | | - Stephen K Tyring
- Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA
- Center for Clinical Studies, Houston, TX, USA
| |
Collapse
|